Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02494570 · OUTCOME

Disease Control Rate

A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa · Source last updated 2023-04-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
through study completion (up to 72 months)

What was measured

The percentage of patients who achieve confirmed CR or PR or SD ≥12 weeks following study treatment initiation.

Groups in this outcome

Experimental: Nab-Sirolimus

Patients with malignant PEComa were treated with 100 mg/m2 nab-sirolimus (30 mins IV infusion) on Days 1 and 8 in a 21-day cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Experimental: Nab-Sirolimus31

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Experimental: Nab-Sirolimus10Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        10
denoms
  1. counts
    1. group Id
      OG000
      value
      31
    units
    Participants
description
The percentage of patients who achieve confirmed CR or PR or SD ≥12 weeks following study treatment initiation.
groups
  1. description
    Patients with malignant PEComa were treated with 100 mg/m2 nab-sirolimus (30 mins IV infusion) on Days 1 and 8 in a 21-day cycle.
    id
    OG000
    title
    Experimental: Nab-Sirolimus
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
through study completion (up to 72 months)
title
Disease Control Rate
type
POST_HOC
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice